Mielóma multiplex: vizsgálatok itt: Lengyelország
39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Gdansk, Katowice, Lodz, Lublin
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 1/2. fázisTaking peopleA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Where
- Gdansk, Olsztyn, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Gdansk, Katowice, Lodz, Lublin, Walbrzych, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Cracow, Gdansk, Katowice, Kielce, Lodz, Skorzewo, Warsaw
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00 - 2. fázisNot yet taking people in LengyelországA Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
- Where
- Brzozów, Gdansk, Gliwice, Katowice, Krakow, Lublin, Olsztyn, Rzeszów, Slupsk, Szczecin, Torun, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 418
- Run by
- Instytut Hematologii I Transfuzjologii
See details and how to join2026-525418-67-00 · EU 2026-525418-67-00 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Gdansk, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Brzozów, Bydgoszcz, Katowice, Kielce, Lodz, Lublin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 3. fázisTaking peopleA Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Bydgoszcz, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lublin, Szczecin, Wroclaw
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Katowice, Krakow, Skórzewo, Słupsk, Torun, Warsaw
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 2. fázisTaking peopleA Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Bydgoszcz, Gdansk, Katowice, Wroclaw
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Gdansk, Lodz, Lublin
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Gdansk, Katowice, Wroclaw
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Lublin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - 3. fázisTaking peopleA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Gdansk, Gliwice, Kielce, Krakow, Lublin, Wroclaw
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Gdansk, Katowice, Poznan
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 3. fázisTaking peopleA Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Bydgoszcz, Gdansk, Katowice, Lublin, Walbrzych, Warsaw
- Életkor
- 18 év and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00 · EU 2025-523815-12-00 - 3. fázisTaking peopleA Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- Bydgoszcz, Chorzów, Cracow, Gdansk, Katowice, Kielce, Lodz, Lublin, Poznan, Szczecin, Wroclaw
- Életkor
- 18 év and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Gliwice, Katowice, Krakow, Skorzewo (Poznan), Torun
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Cracow, Gdansk, Katowice, Kielce, Skorzewo
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisTaking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Cracow, Gdansk, Poznan, Szczecin, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - 3. fázisNot yet taking people in LengyelországA trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Cracow, Gdansk, Gliwice, Kielce, Lublin, Wroclaw
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00 - 3. fázisTaking peoplePhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Where
- Gdansk, Poznan
- Életkor
- 18 év and over
- People
- 1594 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00 - 3. fázisTaking peopleA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Katowice, Kielce, Krakow, Lublin, Skorzewo
- Életkor
- 18 év and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - 3. fázisTaking peopleA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Where
- Bydgoszcz, Cracow, Legnica, Olsztyn, Slupsk, Torun, Walbrzych
- Életkor
- 18 év and over
- People
- 386 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00 - 3. fázisTaking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657